- Document Number:
20230085942
- Appl. No:
17/826803
- Application Filed:
May 27, 2022
- نبذة مختصرة :
The disclosure provides polymers and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.
- Claim:
1. An amine polymer or a salt thereof comprising a first amine, wherein the first amine is linked to pyrimidine-2,4-diamine or an analog thereof.
- Claim:
2. The amine polymer or a salt thereof of claim 1, wherein the first amine is a primary amine, a secondary amine or tertiary amine.
- Claim:
3. The amine polymer or a salt thereof of claim 1, wherein the amine polymer comprises polyallylamine (PAA), polytriallylamine (TAA), polyvinylamine (PVA), polyethyleneimine (PEI), chitosan or any combination thereof.
- Claim:
4. The amine polymer or a salt thereof of claim 1, wherein the analog is 4-N-(6-hexyl)pyrimidine-2,4,6-triamine.
- Claim:
5. The amine polymer or a salt thereof of claim 1, wherein the amine polymer is cross-linked by a crosslinking agent, and preferably, the crosslinking agent is epichlorohydrin.
- Claim:
6. The amine polymer or a salt thereof of claim 1, further comprising a second amine, wherein the second amine is linked to a moiety characterized by selective adsorption of uric acid or precursor thereof.
- Claim:
7. The amine polymer or a salt thereof of claim 1, wherein the moiety is selected from the group consisting of [chemical expression included] [chemical expression included] a derivative thereof and any combination thereof.
- Claim:
8. An amine polymer or a salt thereof comprising repeat units having at least two formulae selected from the group consisting of: [chemical expression included] and a salt thereof, wherein a, b, c, d, e and f, when applicable, are each independently a positive integer.
- Claim:
9. The amine polymer or a salt thereof of claim 8, wherein the repeat units are [chemical expression included] [chemical expression included] , and wherein the ratio of a:b:c:d:e is 0.15:0.1:0.35:0.15:0.15.
- Claim:
10. A composition comprising an amine polymer or a salt thereof, wherein the amine polymer comprises a first amine linked to pyrimidine-2,4-diamine or an analog thereof, and wherein the amine polymer is produced by (i) linking pyrimidine-2,4-diamine or an analog thereof to the first amine, and (ii) subsequently crosslinking by a crosslinking agent.
- Claim:
11. A process of making a polyallylamine-based copolymer having a general structure of formula (4), [chemical expression included] wherein a, b, c, d, and e are each independently a positive integer and the ratio of a:b:c:d:e is 0.15:0.1 :0.35:0.15:0.15, comprising: (1) mixing polyallylamine with NaOH in an aqueous solution; (2) crosslinking the polyallylamine in the aqueous solution with epichlorohydrin to obtain a crosslinked polyallylamine; (3) grafting 4-N-(6-bromo-hexyl)-pyrimidine-2,4,6-triamine hydrobromide onto the crosslinked polyallylamine at an elevated temperature; and (4) further reacting 1-bromodecane and (6-bromohexyl) trimethylammonium bromide with the grafted polyallylamine at the elevated temperature to yield a polyallylamine-based copolymer in a mixture.
- Claim:
12. The process of claim 11, wherein the elevated temperature in steps (3) and (4) is between 65° C. and 70° C.; and/or the process further comprises: (5) filtering the mixture to obtain a solid of the polyallylamine-based copolymer.
- Claim:
13. A composition comprising a polyallylamine-based copolymer produced by the process of claim 11.
- Claim:
14. A pharmaceutical composition comprising an amine polymer or a salt thereof of any one of claim 1: and a pharmaceutically acceptable excipient, diluent, or carrier.
- Claim:
15. A pharmaceutical composition comprising an amine polymer or a salt thereof of claim 8; and a pharmaceutically acceptable excipient, diluent, or carrier.
- Claim:
16. A method of treating a condition associated with an elevated serum uric acid level, comprising administering to a subject in need thereof the amine polymer or the salt thereof of claim 1.
- Claim:
17. The method of claim 16, wherein the amine polymer binds to uric acid or precursor thereof; and/or said condition is hyperuricemia or gout, and said gout is severe gout, chronic gout, or acute gout; and/or the amine polymer or the salt thereof is administered orally.
- Claim:
18. A method of treating a condition associated with an elevated serum uric acid level, comprising administering to a subject in need thereof the amine polymer or the salt thereof of claim 8.
- Claim:
19. A method of treating a condition associated with an elevated serum uric acid level, comprising administering to a subject in need thereof the polyallylamine-based copolymer produced by the process of claim 11 .
- Claim:
20. A method of treating a condition associated with an elevated serum uric acid level, comprising administering to a subject in need thereof the pharmaceutical composition of claim 14.
- Current International Class:
61; 61; 08
- الرقم المعرف:
edspap.20230085942
Processing Request
No Comments.